Prevalensi dan Pola Sensitivitas Antibiotik Acinetobacter baumannii di RSUP. Dr. M. Djamil Padang

Maudy Octarini Ezeddin✉, Ellyza Nasrul, Eugeny Alia
DOI: https://doi.org/10.25077/mka.v45.i1.p10-16.2022

Abstract

Abstrak

Tujuan: Mengetahui prevalensi dan pola sensitivitas Acinetobacter baumannii di RSUP Dr. M. Djamil Padang. Metode:  Penelitian ini adalah penelitian deskriptif retrospektif, dilakukan di Laboratorium Mikrobiologi pada bulan Januari 2020 hingga Juni 2020. Jumlah sampel penelitian sebanyak 195 yang memenuhi kriteria inklusi dan eklusi. Identifikasi bakteri dan uji sensitivitas menggunakan alat mikrobiologi otomatis (VITEK 2) dengan metode kolorimetri dan turbidimetri. Hasil:  Prevalensi Acinetobacter baumannii pada penelitian ini sebesar 14,7%. Spesimen positif terbanyak dari bangsal penyakit dalam, intensif dewasa, intensif anak dan bedah, masing-masing sebesar 46,7%, 20,5%, 7,2%, 7,2%. Sensitivitas Acinetobacter baumannii terhadap antibiotik paling tinggi adalah amikasin, trimetroprim/sulfametoksazol dan meropenem masing-masing sebesar 74,9%, 67,1%, 62,7%. Resistensi antibiotik paling tinggi didapatkan pada cefazolin, seftriakson dan siprofloksasin masing-masing sebesar 99,3%, 67,0%, 66,2%. Kesimpulan: Prevalensi infeksi Acinetobacter baumannii di RSUP Dr M Djamil 14,7% dengan antibiotik paling sensitif adalah amikasin.

Kata kunci: prevalensi; resistensi; antibiotik; Acinetobacter baumannii; pola antibiotik

 

Keywords

Prevalence; resistance; antibiotics; Acinetobacter baumannii; antibiotic pattern

Full Text:

PDF

References

Wong D, Nielsen TB, Bonomo RA, Pantapalangkoor P, Luna B, Spellberg B. Clinical and pathophysiological overview of Acinetobacter infections: A century of challenges. Clin Microbiol Rev. 2017; 30(1):409–47.

Qin LJ, Wang X. A Review on Acinetobacter Baumannii. Journal of Acute Disease 2019; 8(1): 16-20

Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nat Rev Microbiol. 2018; 16(2):91–102.

Weinberg SE, Villedieu A, Bagdasarian N, Karah N, Teare L, Elamin WF. Control and Management of Multidrug Resistant Acinetobacter Baumanni: A Review of the Evidence and Proposal of Novel Approaches. Infection Prevention in Practices. 2020; 100077; 1-9.

World Health Organization (WHO). Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. 2017. [diunduh tanggal 20 Juni 2021]. Tersedia dari https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

Morris FC, Dexter C, Kostoulias X, Uddin MI, Peleg AY. The Mechanism of Disease Caused by Acinetobacter baumannii. Front Microbiol. 2019; 10(1601): 1-20.

Moubareck CA, Halat DH. Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics. 2020; 9(119):1-29.

Tungadi DK, Sennang N, Rusli B. Prevalence and Characteristic of Multidrug-resistant Acinetobacter baumannii Cases at The Dr. Wahidin Sudirohusodo General Hospital in Makassar. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2019; 25(2): 211-217.

Teerawattanapong N, Panich P, Kulpokin D, Na Ranong S, Kongpakwattana K, Saksinanon A, et al. A Systematic Review of The Burden of Multidrug-resistant Healthcare-associated Infections among Intensive Care Unit Patients in Southeast Asia: The Rise of Multidrug-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol. 2018; 39(5):525–33.

Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, et al. Acinetobacter Infections Prevalence and Frequency Of The Antibiotics Resistance: Comparative Study Of Intensive Care Units Versus Other Hospital Units. Pan Afr Med J. 2016; 23:1–10.

Asif M, Alvi IA, Ur Rehman S. Insight into acinetobacter baumannii: Pathogenesis, global resistance, mechanisms of resistance, treatment options, and alternative modalities. Infect Drug Resist. 2018; 11:1249–60.

Budayanti NS, Suranadi IW, Tarini MA, Violentina GAD, Deva DGS. Antimicrobial Susceptibility Patterns of Acinetobacter baumannii Isolates from ICU and Non ICU Wards. Bali Journal of Anesthesiology. 2019; 3(1):50-4.

Cucunawangsih, Wiwing V, Lugito NPH. Antimicrobial Susceptibility of Multidrug-Resistant Acinetobacter baumanii in a Teaching Hospital: A Two-Year Observation. SciRes. 2015; 5: 85-9.

Shamsizadeh Z, Nikaeen M, Esfahani BN, Mirhoseini SH, Hatamzadeh M, Hassanzadeh A. Detection of antibiotic resistant Acinetobacter baumannii in various hospital environments: Potential sources for transmission of acinetobacter infections. Environ Health Prev Med. 2017; 22(1):1–7.

Lynch JP, Zhanel GG, Clark NM. Infections Due to Acinetobacter baumannii in the ICU: Treatment Option. Seminars in Respiratory and Critical Care Medicine. 2017; 38(03), 311–325.

Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The Importance of Acinetobacter Species in the Hospital Environment. Med Arch. 2018; 72(5): 330-4.

Otero M, Curiel A, Rocha MJ, Aranda A, Preciado S, Vazquez G et al. Acinetobacter baumannii Infections in a Tertiary Care Hospital in Mexico over the Past 13 Years. Chemotherapy. 2013;59: 57–65.

Wolfensberger A, Clack L, Kuster SP, Passerini S, Mody L, Chopra V, et al. Transfer of pathogens to and from patients, healthcare providers, and medical devices during care activity - A systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018; 39(9):1093–107.

Yadav SK, Bhujel R, Hamal P, Mishra SK, Sharma S, Sherchand JB. Burden of Multidrug-Resistant Acinetobacter baumannii Infection in Hospitalized Patients in a Tertiary Care Hospital of Nepal. Infection and Drug Resistance. 2020:13. 725-32.

Butler DA, Biagi M, Tan X, Qasmieh S, Bulman ZP, Wenzler E. Multidrug Resistant Acinetobacter baumannii: Resistance by Any Other Name Would Still be Hard to Treat. Current Infectious Disease Reports. 2019; 21(46): 1-17.

Mulani MS, Kamble EE, Kumkar SN, Tawre MS, Pardesi KR. Emerging Strategies to Combat ESKAPE Pathogens in the Era of Antimicrobial Resistance: A Review. Front Microbiol. 2019; 10: 539.

Santajit S & Indrawattana N. Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens. BioMed Research International. 2016, 1–8.

World Health Organization (WHO). Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in health care facilities. 2017. [diunduh tanggal 11 November 2021]. Tersedia dari https://apps.who.int/iris/bitstream/handle/10665/259462/9789241550178-eng.pdf?sequence=1&isAllowed=y



Bookmark and Share
-->